PR Newswire
SANTA BARBARA, Calif. , June 10, 2021 /PRNewswire/ -- Bexson Biomedical, Inc., a research-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, will present details on its R&D pipeline and give a corporate update at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Conference on June 17th.
Facilitated by HC Wainwright & Co, one of the largest investment banks for the biotech industry, the virtual event is set to feature researchers, scientists and business leaders in the emerging psychedelic space.
Gregg Peterson , CEO, will showcase the organization's research around its BB106 subcutaneous ketamine formulation as an alternative to opioid-based pain medications, the company's wearable device, and larger pipeline. The on-demand session will be viewable starting at 7 am EDT on Thursday , June 17th .
Earlier this year, Bexson was granted its first patent for a ketamine formulation that is specifically tuned to the pH and osmolality of subcutaneous tissue. This patent represents Bexson ' s first application of these innovations to enable a subcutaneous ketamine delivery platform designed for management of pain disorders and mental health conditions. In a parallel, Bexson is developing a wearable patch pump in partnership with Italian drug delivery and medical device manufacturer, Stevanato Group, to allow for controlled delivery from a pre-filled, pre-sterilized wearable device.
For more information about the event, visit: https://hcwevents.com/psychedelics/
Bexson Biomedical, Inc . is a research stage company developing therapies for a wide variety of pain management, addiction and mental health disorders. The company's lead indication for its BB106 therapy is acute pain management. Post-operative pain management is a $12 billion market and a leading cause of opioid abuse and addiction. Visit at: www.bexsonbiomedical.com .
SOURCE Bexson Biomedical